Amundi Sells 59,359 Shares of DaVita Inc. $DVA

Amundi trimmed its position in DaVita Inc. (NYSE:DVA) by 11.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 458,331 shares of the company’s stock after selling 59,359 shares during the period. Amundi’s holdings in DaVita were worth $65,340,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Norges Bank purchased a new stake in shares of DaVita in the second quarter worth $32,986,000. Doma Perpetual Capital Management LLC increased its stake in DaVita by 172.3% in the 1st quarter. Doma Perpetual Capital Management LLC now owns 288,360 shares of the company’s stock worth $44,110,000 after acquiring an additional 182,476 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of DaVita in the 2nd quarter valued at about $21,554,000. Arrowstreet Capital Limited Partnership boosted its position in shares of DaVita by 132.1% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock valued at $37,619,000 after acquiring an additional 150,318 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of DaVita by 20.2% during the first quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock worth $136,240,000 after purchasing an additional 149,858 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

Shares of DaVita stock opened at $117.00 on Tuesday. DaVita Inc. has a 52-week low of $113.97 and a 52-week high of $179.60. The company has a fifty day moving average of $123.39 and a 200-day moving average of $132.58. The stock has a market capitalization of $8.26 billion, a price-to-earnings ratio of 12.05, a price-to-earnings-growth ratio of 0.89 and a beta of 0.99.

DaVita (NYSE:DVA) last issued its earnings results on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). The business had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.43 billion. DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.DaVita’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.59 EPS. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, equities research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on DVA shares. Bank of America lowered their target price on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a research note on Wednesday, September 10th. Zacks Research raised shares of DaVita from a “strong sell” rating to a “hold” rating in a report on Friday, November 28th. Barclays dropped their price objective on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a report on Thursday, October 30th. TD Cowen cut their target price on shares of DaVita from $154.00 to $133.00 and set a “hold” rating for the company in a research report on Monday, November 3rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a research report on Monday, December 1st. Six research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $148.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.